Lucid Diagnostics closes $18M underwritten offering of 18M shares at $1.00/share

Lucid Diagnostics Inc.

Closed sale of 18,000,000 shares at $1.00/share; gross proceeds $18M, net proceeds ~$16.8M.
Net proceeds to be used for working capital and general corporate purposes.
Joint bookrunners: Canaccord Genuity LLC and BTIG, LLC.
Offering anchored by $15M investment from fundamental institutional investor and support from a large existing shareholder.
Offered under effective shelf registration statement on Form S-3 declared effective March 26, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.